摘要
卡介苗(Bacille Calmette-Guérin,BCG)目前仍是WHO推荐预防结核病(tuberculosis,TB)的唯一疫苗,对儿童中的结核性脑膜炎及播散性TB具有较好的预防作用,可降低重症TB的风险。虽然新生儿接种BCG效果肯定,但对多数成人肺部疾病的预防作用不一,防治效果差异显著。本文对TB及BCG免疫现状,BCG菌种特性、生产工艺、质量标准、质量风险、接种和接种后异常反应,以及发展现状和发展趋势等方面作一综述,并对BCG的发展及改进提出建议,对BCG的非特异性保护作用及新型TB疫苗的研究进展进行展望。
Bacille Calmette-Guérin(BCG)is still the only vaccine recommended by WHO to prevent tuberculosis(TB),which has a good preventive effect on tuberculous meningitis and disseminated TB in children and can reduce the risk of severe TB.Although the effect of neonatal vaccination with BCG is positive,the preventive effects on most adult lung diseases are significantly different.In this paper,the immunization status of TB and BCG,characteristics of BCG strains,production technology,quality standard,quality risk,vaccination and abnormal reactions after vaccination,as well as the development status and trend are reviewed,while the suggestions on the development and improvement of BCG are put forward,and the nonspecific protective effect of BCG and the progress in research on novel TB vaccines are prospected.
作者
蒋加庆
景辉(综述)
李秀玲(审校)
JIANG Jia-qing;JING Hui;LI Xiu-ling(Slanghai Institute of Biological Products Co.,Ltd.,Shanghai 201403,China)
出处
《中国生物制品学杂志》
CAS
CSCD
北大核心
2021年第10期1260-1268,共9页
Chinese Journal of Biologicals
基金
国家“重大传染病专项”科技重大专项资助项目(2012ZX-10003008-003)。
关键词
卡介苗
结核病
疫苗
工艺
质量
Bacille Calmette-Guérin(BCG)
Tuberculosis
Vaccine
Process
Quality
作者简介
通信作者:李秀玲,E-mail:lixiuling@sinopharm.com。
